Nicoll Avril, Brady Marian C, Masterson-Algar Patricia, Burton Christopher, Beaton Gillian, Dickson Sylvia, Caulfield Maria, Smith Christina H, Clarke Carl E, Ives Natalie, Jowett Sue, Rick Caroline, Woolley Rebecca, Sackley Catherine M
Aberdeen Centre for Women's Health Research, University of Aberdeen, Aberdeen, UK.
School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
Int J Lang Commun Disord. 2025 Jul-Aug;60(4):e70084. doi: 10.1111/1460-6984.70084.
As people with Parkinson's experience progressive communication changes, effective, implementable speech and language therapy (SLT) interventions are needed. Process evaluations alongside pragmatic randomised controlled trials (RCTs) are of clinical value if they describe, compare and understand the implementation of trial interventions. This paper reports the PD COMM process evaluation. PD COMM was a large, UK multi-centre phase III pragmatic RCT of SLT in the National Health Service (NHS). It recruited 388 people with Parkinson's who were randomised to Lee Silverman Voice Treatment (LSVT), Standard NHS SLT, or no dysarthria intervention.
To describe and compare the content and service delivery components of the PD COMM SLT interventions; understand experiences of implementing LSVT; explain trial outcomes; and reflect on implications for practice and research.
We took a pragmatic, mixed methods approach. The intervention description team used a sub-sample of routine therapy notes and trial record forms, the Template for Intervention Description and Replication (TIDieR) and simple descriptive statistics to compare Individual Participant Therapy Data (LSVT n = 51; Standard NHS SLT n = 54). In parallel, informed by Normalisation Process Theory (NPT), the implementation team conducted qualitative interviews with a sub-sample of therapists (n = 20) and participants (n = 24) to understand the additional work of implementing LSVT. The core process evaluation team met to integrate the findings in relation to the trial outcomes.
LSVT was largely delivered per protocol, tailored to participants' interests and interactions. Dosage was a key difference between the two interventions, commonly achieved by two or more therapists delivering LSVT. Effective mechanisms were LSVT's structured design, repetitive and social nature, practise requirements and focus on volume. Standard NHS SLT was eclectic, reflecting a range of clinical approaches at a lower intensity, including some techniques and activities in common with LSVT. Although focused on impairment therapy, including specific voice therapy techniques, it also featured cognitive-linguistic and psychosocial targets and low technology augmentative and alternative communication (AAC). The trial design may have limited opportunities for group intervention.
Any LSVT roll-out needs service support and coordination, and should take an inclusive approach. Future research of Standard NHS SLT should explore a rationale for dosage and more explicit tailoring to individuals and their families. There is also a pressing need to deliver the benefits of LSVT in a cost-effective manner and to develop a range of evidence-based, implementable alternatives as people's communication support needs change.
What is already known on the subject Lee Silverman Voice Treatment (LSVT) has a body of incrementally-developed evidence from effectiveness trials but has not previously been tested in a pragmatic randomised controlled trial (RCT) with an embedded process evaluation. What this paper adds to the existing knowledge This mixed methods process evaluation paper describes and compares content and service delivery components to understand similarities and differences between LSVT and Standard NHS SLT interventions and experiences of implementing LSVT in the UK NHS. What are the potential or actual clinical implications of this work? Services can use the findings to plan delivery of intensive interventions and to reflect on the content and service delivery aspects of locally Standard NHS SLT and how it might be improved.
随着帕金森病患者的沟通能力逐渐出现变化,需要有效且可实施的言语和语言治疗(SLT)干预措施。如果过程评估能描述、比较并理解试验干预措施的实施情况,那么其与实用随机对照试验(RCT)一起具有临床价值。本文报告了帕金森病沟通治疗(PD COMM)的过程评估。PD COMM是英国一项大型多中心III期实用RCT,在国民健康服务体系(NHS)中对SLT进行研究。该研究招募了388名帕金森病患者,他们被随机分配接受李·西尔弗曼嗓音治疗(LSVT)、标准NHS SLT或无构音障碍干预。
描述和比较PD COMM SLT干预措施的内容和服务提供组成部分;了解实施LSVT的经验;解释试验结果;并思考对实践和研究的启示。
我们采用了实用的混合方法。干预描述团队使用常规治疗记录和试验记录表的子样本、干预描述与复制模板(TIDieR)以及简单描述性统计方法,比较个体参与者治疗数据(LSVT组n = 51;标准NHS SLT组n = 54)。同时,在归一化过程理论(NPT)的指导下,实施团队对治疗师子样本(n = 20)和参与者子样本(n = 24)进行了定性访谈,以了解实施LSVT的额外工作。核心过程评估团队开会整合与试验结果相关的研究发现。
LSVT在很大程度上是按照方案实施的,根据参与者的兴趣和互动进行了调整。剂量是两种干预措施的一个关键差异,LSVT通常由两名或更多治疗师实施以达到剂量要求。有效的机制包括LSVT的结构化设计、重复性和社交性、练习要求以及对音量的关注。标准NHS SLT则较为 eclectic,反映了一系列较低强度的临床方法,包括一些与LSVT共有的技术和活动。虽然侧重于障碍治疗,包括特定的嗓音治疗技术,但它也有认知 - 语言和心理社会目标以及低技术辅助和替代沟通(AAC)。试验设计可能限制了团体干预的机会。
任何LSVT的推广都需要服务支持和协调,并且应该采取包容的方法。未来对标准NHS SLT的研究应该探索剂量的理论依据以及更明确地针对个体及其家庭进行调整。随着人们沟通支持需求的变化,迫切需要以具有成本效益的方式提供LSVT的益处,并开发一系列基于证据且可实施的替代方案。
关于该主题已知的信息 李·西尔弗曼嗓音治疗(LSVT)有一系列来自有效性试验的逐步积累的证据,但此前尚未在嵌入过程评估的实用随机对照试验(RCT)中进行测试。本文对现有知识的补充 这篇混合方法过程评估论文描述并比较了内容和服务提供组成部分,以了解LSVT与标准NHS SLT干预措施之间的异同,以及在英国NHS中实施LSVT的经验。这项工作的潜在或实际临床意义是什么?服务机构可以利用这些发现来规划强化干预措施的实施,并思考当地标准NHS SLT的内容和服务提供方面以及如何改进。